KR20150015488A - 2-아미노-4-아릴티아졸 화합물의 아미드 및 그의 염 - Google Patents

2-아미노-4-아릴티아졸 화합물의 아미드 및 그의 염 Download PDF

Info

Publication number
KR20150015488A
KR20150015488A KR1020147033855A KR20147033855A KR20150015488A KR 20150015488 A KR20150015488 A KR 20150015488A KR 1020147033855 A KR1020147033855 A KR 1020147033855A KR 20147033855 A KR20147033855 A KR 20147033855A KR 20150015488 A KR20150015488 A KR 20150015488A
Authority
KR
South Korea
Prior art keywords
formula
compound
trifluoromethyl
tetrahydrothieno
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020147033855A
Other languages
English (en)
Korean (ko)
Inventor
수레쉬 마하데브 카담
아브라함 토마스
수쿠마르 신하
수케르티 쿠마르
비핀 파르소탐 칸사그라
사친 가베인
산딥 반두 칸다게일
샤일레시 파와스
자얀트 프라카슈라오 파틸
샤일렌드라 바데인
바브나 미슈라
라제시 드위베디
Original Assignee
그렌마크 파머수티칼스 에스. 아.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150015488(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 그렌마크 파머수티칼스 에스. 아. filed Critical 그렌마크 파머수티칼스 에스. 아.
Publication of KR20150015488A publication Critical patent/KR20150015488A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020147033855A 2012-06-08 2013-06-08 2-아미노-4-아릴티아졸 화합물의 아미드 및 그의 염 Abandoned KR20150015488A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
IN1687MU2012 2012-06-08
IN1687/MUM/2012 2012-06-08
US201261665282P 2012-06-27 2012-06-27
US61/665,282 2012-06-27
IN3519/MUM/2012 2012-12-13
IN3519MU2012 2012-12-13
US201261748016P 2012-12-31 2012-12-31
US61/748,016 2012-12-31
PCT/IB2013/054703 WO2013183035A2 (en) 2012-06-08 2013-06-08 Amides of 2-amino-4-arylthiazole compounds and their salts

Publications (1)

Publication Number Publication Date
KR20150015488A true KR20150015488A (ko) 2015-02-10

Family

ID=54193746

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147033855A Abandoned KR20150015488A (ko) 2012-06-08 2013-06-08 2-아미노-4-아릴티아졸 화합물의 아미드 및 그의 염

Country Status (22)

Country Link
US (1) US9458173B2 (https=)
EP (1) EP2858999B1 (https=)
JP (1) JP5989900B2 (https=)
KR (1) KR20150015488A (https=)
CN (1) CN104350058A (https=)
AP (1) AP3546A (https=)
AU (1) AU2013273118B2 (https=)
BR (1) BR112014029155A2 (https=)
CA (1) CA2873570C (https=)
CL (1) CL2014003317A1 (https=)
EA (1) EA031334B1 (https=)
HK (1) HK1207643A1 (https=)
IL (1) IL236084A0 (https=)
IN (1) IN2014MN02467A (https=)
MX (1) MX354014B (https=)
MY (1) MY165622A (https=)
NZ (1) NZ701721A (https=)
PE (1) PE20142306A1 (https=)
PH (1) PH12014502685B1 (https=)
SG (1) SG11201408093PA (https=)
WO (1) WO2013183035A2 (https=)
ZA (1) ZA201500082B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026235B1 (ru) 2012-06-08 2017-03-31 Джилид Сайэнс, Инк. Макроциклические ингибиторы вирусов flaviviridae
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
EP3010489A1 (en) 2013-06-20 2016-04-27 Glenmark Pharmaceuticals S.A. Nanoparticulate formulation comprising a trpa1 antagonist
EP3180345B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
WO2016042501A1 (en) * 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
TW202321229A (zh) 2021-08-18 2023-06-01 美商富曼西公司 殺真菌的取代的雜環化合物
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
US6890923B2 (en) 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
AU2003290066A1 (en) 2002-12-18 2004-07-09 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
EP1657238A4 (en) 2003-08-22 2008-12-03 Takeda Pharmaceutical CONDENSATE PYRIMIDINE DERIVATIVE AND ITS USE
WO2005077959A1 (en) 2004-02-11 2005-08-25 Smithkline Beecham Corporation Pth agonists
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
WO2006083005A1 (ja) 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
JP2009503107A (ja) 2005-08-04 2009-01-29 アポジー・バイオテクノロジー・コーポレイション スフィンゴシンキナーゼ阻害剤およびそれらの使用方法
US20070105920A1 (en) 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
JP5858557B2 (ja) * 2005-12-22 2016-02-10 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 疼痛を処置するためのｔｒｐａ１阻害剤
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
CN101454318A (zh) * 2006-03-22 2009-06-10 阿斯利康(瑞典)有限公司 吡啶并嘧啶衍生物及其作为pde4抑制剂的用途
JP2011201776A (ja) 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ヘテロシクリデン−ｎ−（３，４−ジヒドロ−２（１ｈ）−キナゾリノン−５−イル）アセトアミド誘導体
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
JP2010530901A (ja) * 2007-06-22 2010-09-16 ハイドラ バイオサイエンシズ インコーポレイテッド 障害を治療するための方法および組成物
WO2010004390A1 (en) * 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
AP3280A (en) 2009-03-23 2015-05-31 Glenmark Pharmaceuticals Sa Fused pyrimidine-dione derivatives as TRPA1 modulators
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
DK2411397T3 (da) 2009-03-23 2013-08-05 Glenmark Pharmaceuticals Sa Isothiazol-pyrimidindionderivater som modulatorer af TRPA1
PT2411395E (pt) * 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de furopirimidinadiona como moduladores de trpa1
JP5694560B2 (ja) 2010-12-20 2015-04-01 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニストとしての２−アミノ−４−アリールチアゾール化合物

Also Published As

Publication number Publication date
BR112014029155A2 (pt) 2017-06-27
EA201492054A1 (ru) 2016-08-31
MX354014B (es) 2018-02-08
PH12014502685A1 (en) 2015-01-26
NZ701721A (en) 2016-03-31
WO2013183035A3 (en) 2014-02-27
SG11201408093PA (en) 2015-01-29
US9458173B2 (en) 2016-10-04
AU2013273118B2 (en) 2015-11-05
MY165622A (en) 2018-04-18
EA031334B1 (ru) 2018-12-28
JP2015520183A (ja) 2015-07-16
AU2013273118A1 (en) 2014-11-27
ZA201500082B (en) 2015-12-23
EP2858999A2 (en) 2015-04-15
EP2858999B1 (en) 2017-05-10
IN2014MN02467A (https=) 2015-07-10
HK1207643A1 (en) 2016-02-05
MX2014014482A (es) 2015-06-05
CA2873570C (en) 2016-11-01
IL236084A0 (en) 2015-02-01
CL2014003317A1 (es) 2015-02-13
AP3546A (en) 2016-01-14
PH12014502685B1 (en) 2015-01-26
US20150111038A1 (en) 2015-04-23
AP2014008076A0 (en) 2014-11-30
PE20142306A1 (es) 2015-01-16
CA2873570A1 (en) 2013-12-12
CN104350058A (zh) 2015-02-11
WO2013183035A2 (en) 2013-12-12
JP5989900B2 (ja) 2016-09-07

Similar Documents

Publication Publication Date Title
CA2873570C (en) Amides of 2-amino-4-arylthiazole compounds and their salts as trpa1 modulators
EP0693478B1 (en) Quinoline compounds
US5736549A (en) Hypoxanthine and guanine compounds
EA024681B1 (ru) Имидазопиридины в качестве противовирусных средств против респираторно-синцитиального вируса
AP877A (en) Tetrahydroquinoline derivatives as EAA antagonists.
JP3939246B2 (ja) インドロキナゾリノン類
JP2019504103A (ja) Ｔｌｒ７アゴニストのトリフルオロ酢酸塩及びその結晶形ｂ、調製方法、並びに使用
JP2023553291A (ja) Ｔｒｐｍ３媒介性障害を治療するためのアリール誘導体
EP0682021A1 (de) Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP2019505532A (ja) Ｔｌｒ７アゴニストのマレイン酸塩、その結晶形ｃ、ｄ及びｅ、マレイン酸塩及び結晶形の調製方法及び使用
JP3014001B2 (ja) 興奮性アミノ酸拮抗剤
KR20090106633A (ko) ＰＤＥ5 억제제로서 유용한 6-벤질-2,3,4,7-테트라히드로-인돌로[2,3-ｃ]퀴놀린 화합물
CA3016830A1 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
Sondhi et al. Synthesis, anti-inflammatory and analgesic activity evaluation of some pyrimidine derivatives
FI81340C (fi) Foerfarande foer framstaellning av nya, terapeutiskt anvaendbara oxindolkarboxamidderivat.
CN113278012B (zh) 用作激酶抑制剂的化合物及其应用
RU2162470C2 (ru) 2,7-замещенные производные октагидропирроло[1,2-а]пиразина, способ лечения, фармацевтическая композиция, промежуточные соединения
PL173738B1 (pl) Sposób wytwarzania pochodnych pirolo(2,3-d)pirymidyny
EP0260491B1 (en) 9-deazaguanines
JP2005501033A (ja) 新規免疫調節性化合物
JPH0336835B2 (https=)
US5281708A (en) 9-Substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors of PNP
JPH06211844A (ja) ベンゾフラン誘導体
Shafik et al. Synthesis of novel 2-[2-(substituted amino) phenethyl]-1H-benzimidazoles; 3, 4-dihydro and 1, 2, 3, 4,-tetrahydropyrimido [1, 6-a]-benzimidazoles as potential antiulcer agents
DD220307A5 (de) Verfahren zur herstellung von polycyclische carbonsaeureverbindungen

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)